

Alzheimer's Disease

REFERENCES

- Allison, A.C. The possible role of vitamin K deficiency in the pathogenesis of Alzheimer's disease and in augmenting brain damage associated with cardiovascular disease. *Med. Hypotheses* 2001; 57(2): 151-5.
- Anon. Idebenone (monograph). *Altern. Med. Rev.* 2001; 6(1): 83-6.
- Anthony, J.C., Breitner, J.C. et al. Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County Study. *Neurology* 2000; 54(11): 2066-71.
- Arai, H., Suzuki, T. et al. A new interventional strategy for Alzheimer's disease by Japanese herbal medicine. *Nippon Ronen Igakkai Zasshi* 2000; 37(3): 212-5.
- Bai, D.L., Tang, X.C. et al. Huperzine A, a potential therapeutic agent for treatment of Alzheimer's disease. *Curr. Med. Chem.* 2000; 7(3): 355-74.
- Barak, Y., Levine, J. et al. Inositol treatment of Alzheimer's disease: a double blind, cross-over placebo controlled trial. *Prog. Neuropsychopharmacol. Biol. Psychiatry* 1996; 20(4): 729-35.
- Bastianetto, S., Ramassamy, C. et al. The Ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by beta-amyloid. *Eur. J. Neurosci.* 2000; 12(6): 1882-90.
- Beal, M.F. Mitochondria, NO and neurodegeneration. *Biochem. Soc. Symp.* 1999; 66: 43-54.
- Behl, C. Vitamin E protects neurons against oxidative cell death in vitro more effectively than 17-beta estradiol and induces the activity of the transcription factor NF-kappaB. *J. Neural Transm.* 2000; 107(4): 393-407.
- Bergamasco, B., Scarzella, L. et al. Idebenone, a new drug in the treatment of cognitive impairment in patients with dementia of the Alzheimer type. *Funct. Neurol.* 1994; 9(3): 161-8.
- Bertoni-Freddari, C., Giuli, C. et al. The effect of chronic hydergine treatment on the plasticity of synaptic junctions in the dentate gyrus of aged rats. *J. Gerontol.* 1987; 42(5): 482-6.
- Birks, J., Evans, J.G. et al. Rivastigmine for Alzheimer's disease. *Cochrane Database Syst. Rev.* 2000a; 4.
- Birks, J.S., Melzer, D. et al. Donepezil for mild and moderate Alzheimer's disease. *Cochrane Database Syst. Rev.* 2000b; 4.
- Blusztajn, J.K., Liscovitch, M. et al. Phosphatidylcholine as a precursor of choline for acetylcholine synthesis. *J. Neural Transm. Suppl.* 2000; 24: 247-59.
- Booth, A.A., Khalifah, R.G. et al. In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs). Novel inhibition of post-Amadori glycation pathways. *J. Biol. Chem.* 1997; 272(9): 5430-7.
- Booth, A.A., Khalifah, R.G. et al. Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: comparison with aminoguanidine. *Biochem. Biophys. Res. Commun.* 1996; 220(1): 113-9.
- Bopp-Kistler, I., Ruegger-Frey, B. et al. Vitamin B12 deficiency in geriatrics. *Schweiz. Rundsch. Med. Prax.* 1999; 88(45): 1867-75.
- Bottiglieri, T., Hyland, K. S-Adenosylmethionine levels in psychiatric and neurological disorders: a review. *Acta Neurol. Scand. Suppl.* 1994; 154: 19-26.
- Brusco, L.I., Fainstein, I. et al. Effect of melatonin in selected populations of sleep-disturbed patients. *Biol. Signals Recept.* 1999; 8(1-2): 126-31.

- Brusco, L.I., Marquez, M. et al. Melatonin treatment stabilizes chronobiologic and cognitive symptoms in Alzheimer's disease. *Neuroendocrinol. Lett.* 2000; 21(1): 39-42.
- Butterworth, R.F. Evidence for forebrain cholinergic neuronal loss in congenital ornithine transcarbamylase deficiency. *Metab. Brain Dis.* 2000; 15(1): 83-91.
- Carlson, L.E., Sherwin, B.B. et al. Relationships between dehydroepiandrosterone sulfate (DHEAS) and cortisol (CRT) plasma levels and everyday memory in Alzheimer's disease patients compared to healthy controls. *Horm. Behav.* 1999; 35(3): 254-63.
- Chapman, P.F. Alzheimer's disease: model behaviour. *Nature* 2000; 408(6815): 915-6.
- Cheng, D.H., Ren, H. et al. Huperzine A, a novel promising acetylcholinesterase inhibitor. *Neuroreport* 1996; 8(1): 97-101.
- Christen, Y. Oxidative stress and Alzheimer disease. *Am. J. Clin. Nutr.* 2000; 71(2): 621S-629S.
- Clarke, R., Smith, A.D. et al. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. *Arch. Neurol.* 1998; 55(11): 1449-55.
- Corrigan, F.M., Van Rhijn, A. et al. Essential fatty acids in Alzheimer's disease. *Ann. N.Y. Acad. Sci.* 1991; 640: 250-2.
- Crapper McLachlan, D.R., Dalton, A.J. et al. Intramuscular desferrioxamine in patients with Alzheimer's disease. *Lancet* 1991 Jun 1; 337(8753): 1304-8.
- Crook, T., Petrie, W. et al. Effects of phosphatidylserine in Alzheimer's disease. *Psychopharmacol. Bull.* 1992; 28(1): 61-6.
- Cummings, J.L. Treatment of Alzheimer's disease. *Clin. Cornerstone* 2001; 3(4): 27-39.
- Delwaide, P.J., Gyselynck-Mambourg, A.M. et al. Double-blind randomized controlled study of phosphatidylserine in senile demented patients. *Acta Neurol. Scand.* 1986; 73(2): 136-40.
- Diamond, B.J., Shiflett, S.C. et al. Ginkgo biloba extract: mechanisms and clinical indications. *Arch. Phys. Med. Rehab.* 2000; 81(5): 668-78.
- Doody, R.S. Clinical profile of donepezil in the treatment of Alzheimer's disease. *Gerontology* 1999a; 45(Suppl. 1): 23-32.
- Doody, R.S. Therapeutic standards in Alzheimer disease. *Alzheimer Dis. Assoc. Disord.* 1999b; 13(Suppl. 2): S20-S26.
- Dringenberg, H.C., Laporte, P.P. et al. Increased effectiveness of tacrine by deprenyl co-treatment in rats: EEG and behavioral evidence. *Neuroreport* 2000; 11(16): 3513-6.
- Eastley, R., Wilcock, G.K. et al. Vitamin B12 deficiency in dementia and cognitive impairment: the effects of treatment on neuropsychological function. *Int. J. Geriatr. Psychiatry* 2000; 15(3): 226-33.
- Eckert, G.P., Cairns, N.J. et al. Piracetam reverses hippocampal membrane alterations in Alzheimer's disease. *J. Neural Transm.* 1999; 106(7-8): 757-61.
- Engel, R.R., Satzger, W. et al. Double-blind cross-over study of phosphatidylserine vs. placebo in patients with early dementia of the Alzheimer type. *Eur. Neuropsychopharmacol.* 1992; 2(2): 149-55.
- Filip, V., Kolibas, E. Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group. *J. Psychiatry Neurosci.* 1999; 24(3): 234-43.
- Fitten, L.J., Perryman, K.M. et al. Treatment of Alzheimer's disease with short- and long-term oral THA and lecithin: a double-blind study. *Am. J. Psychiatry* 1990; 147(2): 239-42.
- Foster, R.H., Plosker, G.L. Donepezil. Pharmacoeconomic implications of therapy. *Pharmacoeconomics* 1999; 16(1): 99-114.
- Gelowitz, D.L., Paterson, I.A. Neuronal sparing and behavioral effects of the antiapoptotic drug, (-)deprenyl, following kainic acid administration. *Pharmacol. Biochem. Behav.* 1999; 62(2): 255-62.

- Giem, P., Beeson, W.L. et al. The incidence of dementia and intake of animal products: preliminary findings from the Adventist Health Study. *Neuroepidemiology* 1993; 12(1): 28-36.
- Goldsmith, H.S. Abdominal omentum transfer and the nervous system. *Lancet* 1985; 1(8444): 1514.
- Goldsmith, H.S., Chen, W.F. et al. Brain vascularization by intact omentum. *Arch. Surg.* 1973; 106(5): 695-8.
- Goldsmith, H.S., Griffith, A.L. et al. Lipid angiogenic factor from omentum. *JAMA* 1984a; 252(15): 2034-6.
- Goldsmith, H.S., Steward, E. Vascularization of brain and spinal cord by intact omentum. *Appl. Neurophysiol.* 1984b; 47(1-2): 57-61.
- Goldsmith, H.S., McIntosh, T. et al. Vasoactive neurochemicals identified in omentum: a preliminary report. *Br. J. Neurosurg.* 1987; 1(3): 359-64.
- Gottfries, C.G., Lehmann, W. et al. Early diagnosis of cognitive impairment in the elderly with the focus on Alzheimer's disease. *J. Neural Transm.* 1998; 105(8-9): 773-86.
- Grilli, M.M.M. Nuclear factor-kappaB/Rel proteins: a point of convergence of signalling pathways relevant in neuronal function and dysfunction. *Biochem. Pharmacol.* 1999; 57(1): 1-7.
- Grobe-Einsler, R. Clinical aspects of nimodipine. *Clin. Neuropharmacol.* 1993; 16(Suppl. 1): S39-S45.
- Grundman, M. Vitamin E and Alzheimer disease: the basis for additional clinical trials (1). *Am. J. Clin. Nutr.* 2000; 71(2, Pt. 2): 630S-636S.
- Gustilo, M.C., Markowska, A.L. et al. Evidence that nerve growth factor influences recent memory through structural changes in septohippocampal cholinergic neurons. *J. Comp. Neurol.* 1999; 405(4): 491-507.
- Hamon, C.G., Blair, J.A. et al. The effect of tetrahydrofolate on tetrahydrobiopterin metabolism. *J. Mental Deficiency Res.* 1986; 30 (Pt. 2): 179-83.
- Harkness, R., Bratman, S. *Drug-Herb-Vitamin Interactions Bible* 2000. Roseville, CA: Prima Publishing.
- Heiss, W.D., Kessler, J. et al. Long-term effects of phosphatidylserine, pyritinol, and cognitive training in Alzheimer's disease. A neuropsychological, EEG, and PET investigation. *Dementia* 1994; 5(2): 88-98.
- Higgins, J.P., Flicker, L. Lecithin for dementia and cognitive impairment. *Cochrane Database Syst. Rev.* 2000; 4.
- Hillen, T., Lun, A. et al. DHEA-S plasma levels and incidence of Alzheimer's disease. *Biol. Psychiatry* 2000; 47(2): 161-3.
- Hipkiss, A.R. Carnosine, a protective, anti-ageing peptide? *Int. J. Biochem. Cell Biol.* 1998; 30(8): 863-8.
- Hipkiss, A.R., Preston, J.E. et al. Pluripotent protective effects of carnosine, a naturally occurring dipeptide. *Ann. N.Y. Acad. Sci.* 1998; 854: 37-53.
- Horning, M.S., Blakemore, L.J. et al. Endogenous mechanisms of neuroprotection: role of zinc, copper, and carnosine. *Brain Res.* 2000; 852(1): 56-61.
- Horrocks, L.A., Yeo, Y.K. Health benefits of docosahexaenoic acid (DHA). *Pharmacol. Res.* 1999; 40(3): 211-25.
- Huang, W., Alexander, G.E. et al. High brain myo-inositol levels in the predementia phase of Alzheimer's disease in adults with Down's syndrome: a 1H MRS study. *Am. J. Psychiatry* 1999; 156(12): 1879-86.
- Hull, M.S., Stauss, S. et al. Inflammatory mechanisms in Alzheimer's disease. *Eur. Arch. Psychiatry Clin. Neurosci.* 1996; 246(3): 124-8.
- Iwamoto, N.N., Nishiyama, E. Demonstration of CRP immunoreactivity in brains of Alzheimer's disease: immunohistochemical study using formic acid pretreatment of tissue sections. *Neurosci. Lett.* 1994; 177: 1-2.

Jain, K.K. Evaluation of memantine for neuroprotection in dementia. *Expert Opin. Invest. Drugs* 200; 9(6): 1397-1406.

Jimenez-Jimenez, F.J., de Bustos, F. et al. Cerebrospinal fluid levels of alpha-tocopherol (vitamin E) in Alzheimer's disease. *J. Neural Transm.* 1997; 104(6-7): 703-10.

Jimenez-Jimenez, F.J., Molina, J. A. et al. Serum levels of beta-carotene, alpha-carotene and vitamin A in patients with Alzheimer's disease. *Eur. J. Neurol.* 1999; 6(4): 495-7.

Joe, B., Lakesh, B.R. Effect of curcumin and capsaicin on arachidonic acid metabolism and lysosomal enzyme secretion by rat peritoneal macrophages. *Lipids* 1997; 32(11): 1173-80.

Joosten, E., Lesaffre, E. et al. Is metabolic evidence for vitamin B-12 and folate deficiency more frequent in elderly patients with Alzheimer's disease? *J. Gerontol. A Biol. Sci. Med. Sci.* 1997; 52(2): M76-M79.

Kalmijn, S., Launer, L.J. et al. Dietary fat intake and the risk of incident dementia in the Rotterdam Study. *Ann. Neurol.* 1997; 42(5): 776-82.

Kay, A.D., Milstien, S. et al. Cerebrospinal fluid bipterin is decreased in Alzheimer's disease. *Arch. Neurol.* 1986; 43(10): 996-9.

Khalsa, D.S. *Brain Longevity* 1997. New York: Warner Books.

Kidd, P.M. A review of nutrients and botanicals in the integrative management of cognitive dysfunction. *Altern. Med. Rev.* 1999; 4(3): 144-61.

King, R.G. Do raised brain aluminium levels in Alzheimer's dementia contribute to cholinergic neuronal deficits? *Med. Hypotheses* 1984; 14(3): 301-6.

Kontush, A., Mann, U. et al. Influence of vitamin E and C supplementation on lipoprotein oxidation in patients with Alzheimer's disease. *Free Radic. Biol. Med.* 2001; 31(3): 345-54.

Kornhuber, J., Weller, M. et al. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. *J. Neural Transm. Suppl.* 1994; 43: 91-104.

Kumar, A.M., Tims, F. et al. Music therapy increases serum melatonin levels in patients with Alzheimer's disease. *Altern. Ther. Health Med.* 1999; 5(6): 49-57.

Kyle, D.J., Schaefer, E. et al. Low serum docosahexaenoic acid is a significant risk factor for Alzheimer's dementia. *Lipids* 1999; 34(Suppl.): S245.

Lahiri, D.K. Melatonin affects the metabolism of the beta-amyloid precursor protein in different cell types. *J. Pineal Res.* 1999; 26(3): 137-46.

Lahiri, D.K., Ghosh, C. Interactions between melatonin, reactive oxygen species, and nitric oxide. *Ann. N.Y. Acad. Sci.* 1999; 893: 325-30.

Le Bars, P.L., Katz, M.M. et al. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. *JAMA* 1997; 278(16): 1327-32.

Le Bars, P.L., Kieser, M. et al. A 26-week analysis of a double-blind, placebo-controlled trial of the Ginkgo biloba extract EGb 761 in dementia. *Dement. Geriatr. Cogn. Disord.* 2000; 11(4): 230-7.

Leblhuber, F., Walli, J. et al. Hyperhomocysteinemia in dementia. *J. Neural Transm.* 2000; 107(12): 1469-74.

Lehmann, M., Gottfries, C.G. et al. Identification of cognitive impairment in the elderly: homocysteine is an early marker. *Dement. Geriatr. Cogn. Disord.* 1999; 10(1): 12-20.

Lim, G.P., Yang, F. et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. *J. Neurosci.* 2000; 20(15): 5709-14.

- Little, A., Levy, R. et al. A double-blind, placebo controlled trial of high-dose lecithin in Alzheimer's disease. *J. Neurol. Neurosurg. Psychiatry* 1985; 48(8): 736-42.
- Liu, R.Y., Zhou, J.N. et al. Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein E-epsilon 4/4 genotype. *J. Clin. Endocrinol. Metab.* 1999; 84(1): 323-7.
- Lopez-Arrieta, J.M., Rodriguez, J.L. et al. Efficacy and safety of nicotine on Alzheimer's disease patients. *Cochrane Database Syst. Rev.* 2001; 2.
- Mackenzie, I.R., Munoz, D.G. Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. *Neurology* 1998; 50(4): 986-90.
- Magri, F., Terenzi, F. et al. Association between changes in adrenal secretion and cerebral morphometric correlates in normal aging and senile dementia. *Dement. Geriatr. Cogn. Disord.* 2000; 11(2): 90-9.
- Martin, J.B. Molecular basis of the neurodegenerative disorders. *N. Engl. J. Med.* 1999; 340(25): 1970-80.
- Maurizi, C.P. The therapeutic potential for tryptophan and melatonin: possible roles in depression, sleep, Alzheimer's disease and abnormal aging. *Med. Hypotheses* 1990; 31(3): 233-42.
- McCaddon, A., Davies, G. et al. Total serum homocysteine in senile dementia of Alzheimer type. *Int. J. Geriatr. Psychiatry* 1998; 13(4): 235-9.
- McCaddon, A., Hudson, P. et al. Analogues, ageing and aberrant assimilation of vitamin B12 in Alzheimer's disease. *Dement. Geriatr. Cogn. Disord.* 2001a; 12(2): 133-7.
- McCaddon, A., Hudson, P. et al. Homocysteine and cognitive decline in healthy elderly. *Dement. Geriatr. Cogn. Disord.* 2001b; 12(5): 309-13.
- McCarty, M.F. Vascular nitric oxide, sex hormone replacement, and fish oil may help to prevent Alzheimer's disease by suppressing synthesis of acute-phase cytokines. *Med. Hypotheses* 1999; 53(5): 369-74.
- McDermott, J.R., Smith, A.I. et al. Brain aluminum in aging and Alzheimer disease. *Neurology* 1979; 29(6): 809-14.
- McGeer, E.G., McGeer, P.L. Brain inflammation in Alzheimer disease and the therapeutic implications. *Curr. Pharmaceut. Design* 1999; 5(10): 821-36.
- McLachlan, D.R., Bergeron, C. et al. Risk for neuropathologically confirmed Alzheimer's disease and residual aluminum in municipal drinking water employing weighted residential histories. *Neurology* 1996; 46(2): 401-5.
- Meins, W., Muller-Thomsen, T. et al. Subnormal serum vitamin B12 and behavioural and psychological symptoms in Alzheimer's disease. *Int. J. Geriatr. Psychiatry* 2000; 15(5): 415-8.
- Miller, J.W. Homocysteine and Alzheimer's disease. *Nutr. Rev.* 1999; 57(4): 126-9.
- Morris, M.C., Beckett, L.A. et al. Vitamin E and vitamin C supplement use and risk of incident Alzheimer disease. *Alzheimer Dis. Assoc. Disord.* 1998; 12(3): 121-6.
- Morrison, L.D., Smith, D.D. et al. Brain S-adenosylmethionine levels are severely decreased in Alzheimer's disease. *J. Neurochem.* 1996; 67(3): 1328-31.
- Muller, W.E., Eckert, G.P. et al. Piracetam: novelty in a unique mode of action. *Pharmacopsychiatry* 1999; 1: 2-9.
- Munch, G., Mayer, S. et al. Influence of advanced glycation end-products and AGE-inhibitors on nucleation-dependent polymerization of beta-amyloid peptide. *Biochim. Biophys. Acta* 1997; 1360(1): 17-29.
- Murialdo, G., Nobili, F. et al. Hippocampal perfusion and pituitary-adrenal axis in Alzheimer's disease. *Neuropsychobiology* 2000; 42(2): 51-7.
- Nagasawa, H., Kogure, K. et al. Effects of co-dergocrine mesylate (Hydergine) in multi-infarct dementia as evaluated by positron

emission tomography. *Tohoku J. Exp. Med.* 1990; 162(3): 225-33.

Neely, M.D., Zimmerman, L. et al. Congeners of N (alpha)-acetyl-L-cysteine but not aminoguanidine act as neuroprotectants from the lipid peroxidation product 4-hydroxy-2-nonenal. *Free Radic. Biol. Med.* 2000 Nov 15; 29(10): 1028-36.

Newman, P.E. Alzheimer's disease revisited. *Med. Hypotheses* 2000; 54(5): 774-6.

Newman, P.E. Could diet be one of the causal factors of Alzheimer's disease? *Med. Hypotheses* 1992; 39(2): 123-6.

Nishizaki, T., Matsuoka, T. et al. Presynaptic nicotinic acetylcholine receptors as a functional target of nefiracetam in inducing a long-lasting facilitation of hippocampal neurotransmission. *Alzheimer Dis. Assoc. Disord.* 2000; 14(Suppl. 1): S82-S94.

Nitta, A., Hasegawa, T. et al. Oral administration of idebenone, a stimulator of NGF synthesis, recovers reduced NGF content in aged rat brain. *Neurosci. Lett.* 1993; 163(2): 219-22.

Nitta, A., Murakami, Y. et al. Oral administration of idebenone induces nerve growth factor in the brain and improves learning and memory in basal forebrain-lesioned rats. *Naunyn Schmiedebergs Arch. Pharmacol.* 1994; 349(4): 401-7.

Olin, J., Schneider, L. et al. Hydergine for dementia. *Cochrane Database Syst. Rev.* 2000; 2.

Otsuka, M. Analysis of dietary factors in Alzheimer's disease: clinical use of nutritional intervention for prevention and treatment of dementia. *Nippon Ronen Igakkai Zasshi* 2000; 37(12): 970-3 (in Japanese).

Paganini-Hill, A., Henderson, V.W. Estrogen deficiency and risk of Alzheimer's disease in women. *Am. J. Epidemiol.* 1994; 140(3): 256-61.

Paganini-Hill, A., Henderson, V.W. Estrogen replacement therapy and risk of Alzheimer disease. *Arch. Intern. Med.* 1996; 156(19): 2213-7.

Pappolla, M.A., Chyan, Y.J. et al. Alzheimer beta protein mediated oxidative damage of mitochondrial DNA: prevention by melatonin. *J. Pineal Res.* 1999; 27(4): 226-9.

Park, H., Jang, J. et al. A concise synthetic pathway for trans-metanicotine analogues. *Arch. Pharm. Res.* 2000; 23(3): 202-5.

Perlmutter, D. *BrainRecovery.com* 2000. Naples, FL: The Perlmutter Health Center.

Perry, E.K., Pickering, A.T. et al. Medicinal plants and Alzheimer's disease: from ethnobotany to phytotherapy. *J. Pharm. Pharmacol.* 1999; 51(5): 527-34.

Peters, B.H., Levin, H.S. Effects of physostigmine and lecithin on memory in Alzheimer disease. *Ann. Neurol.* 1979; 6(3): 219-21.

Pettegrew, J.W., Levine, J. et al. Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer's disease and geriatric depression. *Mol. Psychiatry* 2000; 5(6): 616-32.

Pizzorno, J.E., Murray, M.T. *Alzheimer's Disease. A Textbook of Natural Medicine* 1995. Seattle, WA: Bastyr College Publications.

Pocernich, C.B., La Fontaine, M. et al. In vivo glutathione elevation protects against hydroxyl free radical-induced protein oxidation in rat brain. *Neurochem. Int.* 2000; 36(3): 185-91.

Porter, R.J., Lunn, B.S. et al. Cognitive deficit induced by acute tryptophan depletion in patients with Alzheimer's disease. *Am. J. Psychiatry* 2000; 157(4): 638-40.

Preston, J.E., Hipkiss, A.R. et al. Toxic effects of beta-amyloid (25-35) on immortalised rat brain endothelial cell: protection by carnosine, homocarnosine and beta-alanine. *Neurosci. Lett.* 1998; 242(2): 105-8.

Ramamurthy, B., Hook, P. et al. An overview of carbohydrate-protein interactions with specific reference to myosin and ageing. *Acta Physiol. Scand.* 1999; 167(4): 327-9.

Regland, B., Blennow, K. et al. The role of the polymorphic genes apolipoprotein E and methylene-tetrahydrofolate reductase in the

development of dementia of the Alzheimer type. *Dement. Geriatr. Cogn. Disord.* 1999; 10(4): 245-51.

Reiter, R.J., Cabrera, J. et al. Melatonin as a pharmacological agent against neuronal loss in experimental models of Huntington's disease, Alzheimer's disease and parkinsonism. *Ann. N.Y. Acad. Sci.* 1999; 890: 471-85.

Renvall, M.J., Spindler, A.A. et al. Nutritional status of free-living Alzheimer's patients. *Am. J. Med. Sci.* 1989; 298(1): 20-7.

Riviere, S., Birlouez-Aragon, I. et al. Low plasma vitamin C in Alzheimer patients despite an adequate diet. *Int. J. Geriatr. Psychiatry* 1998; 13(11): 749-54.

Robert, P.H., Gokalsing, E. et al. Cholinergic hypothesis and Alzheimer's disease: the place of donepezil (Aricept). *Encephale* 1999; 5: 23-7.

Sano, M., Ernesto, C. et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. *N. Engl. J. Med.* 1997; 336(17): 1216-22.

Sawada, M., Hirata, Y. et al. Tyrosine hydroxylase, tryptophan hydroxylase, biopterin, and neopterin in the brains of normal controls and patients with senile dementia of Alzheimer type. *J. Neurochem.* 1987; 48(3): 760-4.

Scali, C., Prosperi, C. et al. Brain inflammatory reaction in an animal model of neuronal degeneration and its modulation by an anti-inflammatory drug: implication in Alzheimer's disease. *Eur. J. Neurosci.* 2000; 12(6): 1900-12.

Schofield, P.W., Tang, M. et al. Alzheimer's disease after remote head injury: an incidence study. *J. Neurol. Neurosurg. Psychiatry* 1997; 62(2): 119-24.

Schroeter, H., Williams, R.J. et al. Phenolic antioxidants attenuate neuronal cell death following uptake of oxidized low-density lipoprotein. *Free Radic. Biol. Med.* 2000; 29(12): 1222-33.

Serot, J.M., Christmann, D. et al. CSF-folate levels are decreased in late-onset AD patients. *J. Neural Transm.* 2001; 108(1): 93-9.

Shankaranarayana Rao, B.S., Lakshmana, M.K. et al. Chronic (-) deprenyl administration alters dendritic morphology of layer III pyramidal neurons in the prefrontal cortex of adult Bonnett monkeys. *Brain Res.* 1999; 821(1): 218-23.

Stern, Y., Gurland, B. et al. Influence of education and occupation on the incidence of Alzheimer's disease. *JAMA* 1994; 271(13): 1004-10.

Stewart, W.F., Kawas, C. et al. Risk of Alzheimer's disease and duration of NSAID use. *Neurology* 1997; 48(3): 626-32.

Suuronen, T., Kolehmainen, P. et al. Protective effect of L-deprenyl against apoptosis induced by okadaic acid in cultured neuronal cells. *Biochem. Pharmacol.* 2000; 59(12): 1589-95.

Tabet, N., Birks, J. et al. Vitamin E for Alzheimer's disease. *Cochrane Database Syst. Rev.* 2000; 4.

Tang, X.C. Huperzine A (shuangyiping): a promising drug for Alzheimer's disease. *Zhongguo Yao Li Xue Bao* 1996; 17(6): 481-4.

Tariska, P., Paksy, A. Cognitive enhancement effect of piracetam in patients with mild cognitive impairment and dementia. *Orv. Hetil.* 2000; 141(22): 1189-93.

Thal, L.J., Calvani, M. et al. A 1-year controlled trial of acetyl-L-carnitine in early onset AD. *Neurology* 2000; 55(6): 805-10.

Thal, L.J., Fuld, P.A. et al. Oral physostigmine and lecithin improve memory in Alzheimer disease. *Ann. Neurol.* 1983; 13(5): 491-6.

Thomas, T. Monoamine oxidase-B inhibitors in the treatment of Alzheimer's disease. *Neurobiol. Aging* 2000; 21(2): 343-8.

Thome, J., Kornhuber, J. et al. New hypothesis on etiopathogenesis of Alzheimer syndrome. Advanced glycation end products (AGEs). *Nervenarzt* 1996; 67(11): 924-9.

Trombley, P.Q., Horning, M.S. et al. Interactions between carnosine and zinc and copper: implications for neuromodulation and neuroprotection. *Biochemistry* 2000; 65(7): 807-16.

- van Dongen, M.C., van Rossum, E. et al. The efficacy of ginkgo for elderly people with dementia and age-associated memory impairment: new results of a randomized clinical trial. *J. Am. Geriatr. Soc.* 2000; 48(10): 1183-94.
- Veinbergs, I., Mallory, M. et al. Vitamin E supplementation prevents spatial learning deficits and dendritic alterations in aged apolipoprotein E-deficient mice. *Eur. J. Neurosci.* 2000; 12(12): 4541-6.
- Virmani, M.A., Caso, V. et al. The action of acetyl-L-carnitine on the neurotoxicity evoked by amyloid fragments and peroxide on primary rat cortical neurones. *Ann. N.Y. Acad. Sci.* 2001; 939: 162-78.
- Wang, H.X., Wahlin, A. et al. Vitamin B(12) and folate in relation to the development of Alzheimer's disease. *Neurology* 2001; 56(9): 1188-94.
- Wang, L.M., Han, Y.F. et al. Huperzine A improves cognitive deficits caused by chronic cerebral hypoperfusion in rats. *Eur. J. Pharmacol.* 2000; 398(1): 65-72.
- Wettstein, A. Cholinesterase inhibitors and ginkgo extracts-are they comparable in the treatment of dementia? Comparison of published placebo-controlled efficacy studies of at least six months' duration. *Phytomedicine* 2000; 6(6): 393-401.
- Weyer, G., Babej-Dolle, R.M. et al. A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease. *Neuropsychobiology* 1997; 36(2): 73-82.
- Widner, B., Leblhuber, F. et al. Tryptophan degradation and immune activation in Alzheimer's disease. *J. Neural Transm.* 2000; 107(3): 343-53.
- Winblad, B., Poritis, N. Memantine in severe dementia: results of the 9M-Best Study (benefit and efficacy in severely demented patients during treatment with memantine). *Int. J. Geriatr. Psychiatry* 1999; 14(2): 135-46.
- Wisniewski, H.M., Wen, G.Y. Aluminium and Alzheimer's disease. *Ciba Found. Symp.* 1992; 169: 142-54.
- Xu, S.S., Guo, Z.X. et al. Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease. *Zhongguo Yao Li Xue Bao* 1995; 16(5): 391-5.
- Yaffe, K., Sawaya, G. et al. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. *JAMA* 1998; 279(9): 688-95.
- Yamada, K., Nitta, A. et al. Orally active NGF synthesis stimulators: potential therapeutic agents in Alzheimer's disease. *Behav. Brain Res.* 1997; 83(1-2): 117-22.
- Yamada, K., Tanaka, T. et al. Protective effects of idebenone and alpha-tocopherol on beta-amyloid-(1-42)-induced learning and memory deficits in rats: implication of oxidative stress in beta-amyloid-induced neurotoxicity in vivo. *Eur. J. Neurosci.* 1999; 11(1): 83-90.
- Yao, Z., Drieu, K. et al. The Ginkgo biloba extract EGb 761 rescues the PC12 neuronal cells from beta-amyloid-induced cell death by inhibiting the formation of beta-amyloid-derived diffusible neurotoxic ligands. *Brain Res.* 2001; 889(1-2): 181-90.
- Yao, Z.X., Drieu, K. et al. Free radicals and lipid peroxidation do not mediate beta-amyloid-induced neuronal cell death. *Brain Res.* 1999; 847(2): 203-10.
- Yatin, S.M., Yatin, M. et al. Alzheimer's amyloid beta-peptide associated free radicals increase rat embryonic neuronal polyamine uptake and ornithine decarboxylase activity: protective effect of vitamin E. *Neurosci. Lett.* 1999; 263(1): 17-20.
- Yehuda, S., Rabinovtz, S. et al. Essential fatty acids preparation (SR-3) improves Alzheimer's patients' quality of life. *Int. J. Neurosci.* 1996; 87(3-4): 141-9.
- Youdim, K.A., Martin A. et al. Essential fatty acids and the brain: possible health implications. *Int. J. Dev. Neurosci.* 2000; 18(4-5): 383-99.
- Zhou, L.J., Zhu, X.Z. Reactive oxygen species-induced apoptosis in PC12 cells and protective effect of bilobalide. *J. Pharmacol. Exp. Ther.* 2000; 293(3): 982-8.

Risk Factors

Ashford, J.W., Mortimer, J.A. Non-familial Alzheimer's disease is mainly due to genetic factors. *J. Alzheimers Dis.* 2002 Jun; 4(3): 169-77.

Bowirrat, A., Friedland, R.P., Farrer, L., Baldwin, C., Korczyn, A. Genetic and environmental risk factors for Alzheimer's disease in Israeli Arabs. *J. Mol. Neurosci.* 2002 Aug-Oct; 19(1-2): 239-45.

Crawford, J.G. Alzheimer's disease risk factors as related to cerebral blood flow. *Med. Hypotheses* 1996 Apr; 46(4): 367-77.

Crawford, J.G. Alzheimer's disease risk factors as related to cerebral blood flow: additional evidence. *Med. Hypotheses* 1998 Jan; 50(1): 25-36.

de la Torre, J.C. Alzheimer disease as a vascular disorder: nosological evidence. *Stroke* 2002 Apr; 33(4): 1152-62.

de la Torre, J.C. Cerebromicrovascular pathology in Alzheimer's disease compared to normal aging. *Gerontology* 1997; 43(1-2): 26-43.

de la Torre, J.C. Impaired cerebromicrovascular perfusion. Summary of evidence in support of its causality in Alzheimer's disease. *Ann. N.Y. Acad. Sci.* 2000; 924: 136-52.

Eikelenboom, P., Hoogendijk, W.J., Jonker, C., van Tilburg, W. Immunological mechanisms and the spectrum of psychiatric syndromes in Alzheimer's disease. *J. Psychiatr. Res.* 2002 Sep-Oct; 36(5): 269-80.

Heinonen, O., Syrjanen, S., Mantyjarvi, R., Syrjanen, K., Riekkinen, P. JC virus infection and Alzheimer's disease: reappraisal of an in situ hybridization approach. *Ann. Neurol.* 1992 Apr; 31(4): 439-41.

Itzhaki, R.F., Lin, W.R., Shang, D. et al. Herpes simplex virus type 1 in brain and risk of Alzheimer's disease. *Lancet* 1997 Jan 25; 349(9047): 241-4.

Jorm, A.F. Alzheimer's disease: risk and protection. *Med. J. Aust.* 1997 Oct 20; 167(8): 443-6.

Kidd, P.M. A review of nutrients and botanicals in the integrative management of cognitive dysfunction. *Altern. Med. Rev.* 1999 Jun; 4(3): 144-61.

Kim, S.H., Cairns, N., Fountoulakisc, M., Lubec, G. Decreased brain histamine-releasing factor protein in patients with Down syndrome and Alzheimer's disease. *Neurosci. Lett.* 2001 Mar 2; 300(1): 41-4.

Lindsay, J., Laurin, D., Verreault, R., Hebert, R. et al. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. *Am. J. Epidemiol.* 2002 Sep 1; 156(5): 445-53.

Minger, S.L., Esiri, M.M., McDonald, B. et al. Cholinergic deficits contribute to behavioral disturbance in patients with dementia. *Neurology* 2000 Nov 28; 55(10): 1460-7.

Perry, E., Walker, M., Grace, J., Perry, R. Acetylcholine in mind: a neurotransmitter correlate of consciousness? *Trends Neurosci.* 1999 Jun; 22(6): 273-80.

Ravaglia, G., Forti, P., Maioli, F., Sacchetti, L. et al. Education, occupation, and prevalence of dementia: findings from the Conselice Study. *Dement. Geriatr. Cogn. Disord.* 2002; 14(2): 90-100.

Schofield, P.W., Tang, M., Marder, K. et al. Alzheimer's disease after remote head injury: an incidence study. *J. Neurol. Neurosurg. Psychiatry* 1997 Feb; 62(2): 119-24.

Small, G.W. The pathogenesis of Alzheimer's disease. *J. Clin. Psychiatry* 1998; 59(Suppl. 9): 7-14.

Sparks, D.L., Connor, D.J., Browne, P., Sabbagh, M.N. Should the guidelines for monitoring serum cholesterol levels in the elderly be re-evaluated? *J. Mol. Neurosci.* 2002 Aug-Oct; 19(12): 209-12.

Warkentin, S., Passant, U. Functional imaging of the frontal lobes in organic dementia. Regional cerebral blood flow findings in normals, in patients with frontotemporal dementia and in patients with Alzheimer's disease performing a word fluency test. *Dement.*

These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure or prevent any disease. The information provided on this site is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional or any information contained on or in any product label or packaging. You should not use the information on this site for diagnosis or treatment of any health problem or for prescription of any medication or other treatment. You should consult with a healthcare professional before starting any diet, exercise or supplementation program, before taking any medication, or if you have or suspect you might have a health problem. You should not stop taking any medication without first consulting your physician.